| |
|
|
|
Trillium Therapeutic  
|
|
7 -0.175 (-0.02%) |
04-20 15:59 |
|
Open: |
7.1 |
Pre close: |
7.175 |
Target:
|
9.01
|
|
High: |
7.3 |
Low: |
6.85 |
Resistance:
|
7.71
8.40
|
|
Volume: |
39,593 |
Market Cap: |
87M |
Support:
|
6.60
5.49
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
7.19
 |
MACD |
MACD(12,26):
|
-0.06 |
|
MA(20): |
7.09 |
Signal(12,26,9): |
-0.08  |
|
MA(100): |
7.84 |
Stochastic Oscillator |
%K(14,3):
|
49.96 |
|
MA(250): |
6.56 |
%D(3): |
49.45 |
|
Average Volume(K) |
3-Month: |
7480
|
52-Week |
High:
|
13.30 |
|
10-Days: |
8067 |
Low: |
4.15 |
|
RSI |
RSI(14):
|
45.02 |
Change(%): |
16.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-3.650 |
Return on Equity (ttm) |
-173.7 |
Shares Out. (M) |
13.15 |
|
EPS Est. Current Year |
-4.130 |
Return on Assets (ttm) |
-56.0 |
Shares Float (M) |
13.15 |
|
EPS Est. Next Year |
-2.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
-0.960 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
64.60 |
|
Forward EPS |
-2.925 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
176 |
|
Book Value (p.s.) |
4.440 |
EBITDA (p.s.) |
-1.822 |
P/E |
-1.92 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.58 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-21.12 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-8.55 |
P/CF |
-4.36 |
|
|
|
|
|
|
